Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
Acta Derm Venereol
.
2022 Sep 28:102:adv00780.
doi: 10.2340/actadv.v102.2926.
Authors
Federica Repetto
1
,
Lorenza Burzi
,
Simone Ribero
,
Pietro Quaglino
,
Paolo Dapavo
Affiliation
1
Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy. repettofederica@gmail.com.
PMID:
35971829
PMCID:
PMC9677263
DOI:
10.2340/actadv.v102.2926
No abstract available
MeSH terms
Antibodies, Monoclonal / adverse effects
Hidradenitis Suppurativa* / diagnosis
Hidradenitis Suppurativa* / drug therapy
Humans
Substances
Antibodies, Monoclonal
risankizumab